Skip to main content

Table 1 Univariable and multivariable analyses based on clinical information for astrocytoma and oligodendroglioma

From: Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor

  Univariable Multivariable   Univariable Multivariable
Astrocytoma Group HR (95% CI) P-value C-index HR (95% CI) P-value C-index Oligodendroglioma Group HR (95% CI) P-value C-index HR (95% CI) P-value C-index
TCGA (n = 140) (n/%)        TCGA (n = 94) (n/%)       
Age (y)       0.635 Age (y)       0.959
 < 50 (reference, 119/85%) 1    1    < 50 (reference, 66/70.2%) 1    1  
 50–59 (14/10%) 0.001 (0–Inf) 0.998 0.517 0.001 (0–Inf) 0.998  50–59 (17/18.1%) 2.66 × 109 (0–Inf) 1 0.899 3.37 × 109 (0–Inf) 1
 > 60 (7/5%) 0.85 (0.20–3.63) 0.828 0.72 (0.16–3.26) 0.669  > 60 (11/11.7%) 7.72 × 10–9 (0–Inf) 0.999 5.72 × 10–9 (0–Inf) 0.999
Gender       Gender      
 Female (reference, 67/47.9%) 1    1    Female (reference, 43/45.7%) 1    1  
 Male (73/52.1%) 1.03 (0.48–2.20) 0.943 0.509 1.15 (0.51–2.62) 0.737  Male (51/54.3%) 0.24 (0.03–2.14) 0.203 0.763 0.46 (0.03–7.99) 0.593
Radiotherapy       Radiotherapy      
 No (reference, 69/49.3%) 1    1    No (reference, 68/72.3%) 1    1  
 Yes (71/50.7%) 1.20 (0.55–2.66) 0.646 0.519 1.22 (0.49–3.05) 0.67  Yes (27/28.7%) 0.46 (0.04–4.88) 0.521 0.611 0.26 (0.02–3.11) 0.29
Chemotherapy       Chemotherapy      
 No (reference, 87/62.1%) 1    1    No (reference, 60/63.8%) 1    1  
 Yes (53/37.9%) 1.20 (0.54–2.71) 0.652 0.587 1.17 (0.47–2.93) 0.733  Yes (34/36.2%) 1.4 (0.23–8.54) 0.713 0.361 1.51 (0.22–10.20) 0.67
MGMT       MGMT      
 Unmethylated (reference, 16/11.4%) 1    1    Unmethylated (reference, 1/1.1%) 1    1  
 Methylated (124/88.6%) 0.43 (0.10–1.83) 0.251 0.541 0.38 (0.08–1.71) 0.208  Methylated (93/98.9%) 0.3 × 10–6 (0–Inf) 0.999 0.505 0.36 (0–Inf) 1
ATRX       TERT      
 MT (reference, 108/77.1%) 1    1    MT (reference, 49/52.1%) 1    1  
 WT (32/22.9%) 0.97 (0.39–2.43) 0.956 0.473 0.88 (0.33–2.31) 0.792  WT (2/2.1%) 0.31 (0.04–2.67) 0.284 0.737 0.52 (0.02–11.03) 0.675
DNA methylation        Unclear (43/45.7%) 2.34 × 10–8 (0-Inf) 0.999 1.3 × 10–9 (0–Inf) 1
 G-CIMP-high (reference, 137/97.9%) 1    1         
 Codel (3/2.1%) 9.17 × 104 (0–Inf) 0.998 0.506 2.63 × 105 (0–Inf) 0.999 CGGA cohort 1 (n = 80) (n/%)       
        PRS       0.805
CGGA Cohort 1 (n = 100) (n/%)         Primary (reference, 71/88.8%) 1    1  
PRS       0.672  Recurrent (9/11.3%) 20.05 (6.10–65.91)  < 0.001 0.692 19.64 (4.09–94.27)  < 0.001
 Primary (reference, 81/81.0%) 1    1   Age (y)      
 Recurrent (19/19%) 1.95 (0.97–3.92) 0.059 0.606 3.08 (1.44–6.59) 0.004   < 50 (reference, 70/87.5%) 1    1  
Age (y)        50–59 (8/10%) 9.59 (1.14–80.40) 0.037 0.599 6.88 (0.53–88.75) 0.139
 < 50 (reference, 88/88%) 1    1    > 60 (2/2.5%) 2.83 (0.79–10.12) 0.11 0.64 (0.12–3.34) 0.56
 50–59 (11/11%) 2.69 (0.36–19.87) 0.334 0.556 1.75 (0.22–13.75) 0.593 Gender      
 > 60 (1/1%) 1.93 (0.81–4.62) 0.137 2.4 (0.98–5.89) 0.055  Female (reference, 34/42.5%) 1    1  
Gender        Male (46/57.5%) 0.97 (0.37–2.55) 0.951 0.508 1.09 (0.38–3.13) 0.868
 Female (reference, 37/37%) 1    1   Radiotherapy      
 Male (64/64%) 0.59 (0.32–1.09) 0.092 0.538 0.49 (0.26–0.95) 0.033  No (reference, 13/16.3%) 1    1  
Radiotherapy        Yes (67/83.7%) 0.70 (0.16–3.18) 0.647 0.534 0.53 (0.11–2.60) 0.434
 No (reference, 18/18%) 1    1   Chemotherapy      
 Yes (82/82%) 1.86 (0.73–4.75) 0.194 0.551 2.18 (0.81–5.85) 0.122  No (reference, 50/62.5%) 1    1  
Chemotherapy        Yes (30/37.5%) 3.46 (1.29–9.29) 0.014 0.605 2.2 (0.74–6.53) 0.155
 No (reference, 54/54%) 1            
 Yes (46/46%) 1.52 (0.82–2.81) 0.183 0.545 1 0.403        
  1. HR hazard ratio, 95% CI 95% confidence interval, MGMT O6-methylguanine-DNA methyltransferase, ATRX alpha thalassemia/mental retardation, X-linked, TERT telomerase reverse transcriptase, MT mutant, WT wild type, inf inferential statistics (extremum in statistics)